Long‐Term Outcome of Pulmonary Artery Hypertension‐Specific Therapy in Patients With Portopulmonary Hypertension: A Multi‐Institutional Database Case Series Study
Pulmonary Circulation · 2026-04 · 16 (2)
DOI: 10.1002/pul2.70301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 17.04.2026. Verfasst von Ding-Sen Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH) associated with portal hypertension, occurring in 2%–6% of cirrhotic patients. Although guidelines recommend routine echocardiography before transplantation, the prevalence, and outcomes of PAH‐specific therapy in cirrhotic patients remain unclear. We retrospectively analyzed 4,113 cirrhotic patients who underwent transthoracic echocardiography (TTE) between 2008 and 2019 using the Chang Gung Research Database. Patient characteristics, medication, echocardiographic findings, right heart catheterization (RHC) results and clinical outcome were collected from medical records and retrospectively analyzed by the investigators. Among 3243 patients with completed TTE, 709 (21.9%) had elevated tricuspid regurgitation peak gradient (TRPG ≥ 35 mmHg), suggesting pulmonary hypertension. There were 52 patients underwent RHC at our center, of whom 46 (88.5%) fulfilled hemodynamic criteria for PoPH. Additionally, seven patients with externally confirmed PoPH were included, yielding 53 patients in the final analysis. Among them, 13 patients received PAH‐specific therapy with significant TRPG reduction but shorter mean survival (median survival 22.6 vs 78.9 months, p = 0.037) than those without therapy. Among patients under PAH‐specific therapy, those who had higher baseline TRPG (≧ 50 mmHg), mPAP (≧ 40 mmHg) and pulmonary vascular resistance (≧ 2 Wood Units) were noted with better survival. PoPH is not rare in patients with liver cirrhosis. Exploratory subgroup analyses suggest that selected patients with severe hemodynamic impairment may potentially benefit from PAH‐specific therapy; however, these findings require validation in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan.
ORCID-Profile: Yi-Ting Chen
Zitieren
APA
Huang, D. S., Huang, T. H., Chen, Y. T., Liu, W. H., Chung, S. Y., & Cheng, C. I. (2026). Long‐Term Outcome of Pulmonary Artery Hypertension‐Specific Therapy in Patients With Portopulmonary Hypertension: A Multi‐Institutional Database Case Series Study. Pulmonary Circulation, 16(2). https://doi.org/10.1002/pul2.70301
Vancouver
Huang DS, Huang TH, Chen YT, Liu WH, Chung SY, Cheng CI. Long‐Term Outcome of Pulmonary Artery Hypertension‐Specific Therapy in Patients With Portopulmonary Hypertension: A Multi‐Institutional Database Case Series Study. Pulmonary Circulation. 2026;16(2). doi:10.1002/pul2.70301
BibTeX
@article{Huang2026,
author = {Huang, Ding-Sen and Huang, Ting-Hsin and Chen, Yi-Ting and Liu, Wen-Hao and Chung, Sheng-Ying and Cheng, Cheng-I},
title = {Long‐Term Outcome of Pulmonary Artery Hypertension‐Specific Therapy in Patients With Portopulmonary Hypertension: A Multi‐Institutional Database Case Series Study},
journal = {Pulmonary Circulation},
year = {2026},
volume = {16},
number = {2},
doi = {10.1002/pul2.70301}
}
EUVIMED